IBiTech-BioMMeda Group, Ghent University, Ghent, Belgium.
Interuniversity Institute of Bioinformatics in Brussels, ULB-VUB, Brussels, Belgium.
Proteins. 2024 Feb;92(2):246-264. doi: 10.1002/prot.26607. Epub 2023 Oct 14.
α-1 acid glycoprotein (AGP) is one of the most abundant plasma proteins. It fulfills two important functions: immunomodulation, and binding to various drugs and receptors. These different functions are closely associated and modulated via changes in glycosylation and cancer missense mutations. From a structural point of view, glycans alter the local biophysical properties of the protein leading to a diverse ligand-binding spectrum. However, glycans can typically not be observed in the resolved X-ray crystallography structure of AGP due to their high flexibility and microheterogeneity, so limiting our understanding of AGP's conformational dynamics 70 years after its discovery. We here investigate how mutations and glycosylation interfere with AGP's conformational dynamics changing its biophysical behavior, by using molecular dynamics (MD) simulations and sequence-based dynamics predictions. The MD trajectories show that glycosylation decreases the local backbone flexibility of AGP and increases the flexibility of distant regions through allosteric effects. We observe that mutations near the glycosylation site affect glycan's conformational preferences. Thus, we conclude that mutations control glycan dynamics which modulates the protein's backbone flexibility directly affecting its accessibility. These findings may assist in the drug design targeting AGP's glycosylation and mutations in cancer.
α-1 酸性糖蛋白(AGP)是血浆中最丰富的蛋白之一。它具有两种重要的功能:免疫调节,以及与各种药物和受体结合。这些不同的功能通过糖基化和癌症错义突变的变化密切相关和调节。从结构的角度来看,糖基化改变了蛋白质的局部生物物理特性,导致配体结合谱的多样性。然而,由于其高度的灵活性和微观异质性,糖基通常不能在 AGP 的已解析 X 射线晶体学结构中观察到,这限制了我们对其构象动力学的理解,而其发现至今已有 70 年。我们通过分子动力学(MD)模拟和基于序列的动力学预测来研究突变和糖基化如何干扰 AGP 的构象动力学,从而改变其生物物理行为。MD 轨迹表明,糖基化通过变构效应降低了 AGP 的局部骨架灵活性,并增加了远距离区域的灵活性。我们观察到糖基化位点附近的突变会影响糖的构象偏好。因此,我们得出结论,突变控制糖基化动力学,从而调节蛋白质的骨架灵活性,直接影响其可及性。这些发现可能有助于针对 AGP 的糖基化和癌症中的突变进行药物设计。